GLP-1 Diabetes Drugs Tied to 38% Lower Obesity-Related Cancer Risk Than Insulin, but No Clear Edge Over Metformin
A UT Southwestern study found GLP-1 users with type 2 diabetes had about 38% lower obesity-related cancer risk than insulin users over three years, but researchers stressed the results cannot prove prevention.
Medical Daily ·